Case Report: Severe Eosinophilic Asthma Associated With ANCA-Negative EGPA in a Young Adult Successfully Treated With Benralizumab

Letter Medicine, General & Internal

Benralizumab in eosinophilic granulomatosis with polyangiitis

Daniel Laorden et al.

MEDICINA CLINICA (2022)

Add to Collection

Letter Medicine, General & Internal

Benralizumab in eosinophilic granulomatosis with polyangiitis

Daniel Laorden et al.

MEDICINA CLINICA (2022)

Add to Collection

Article Immunology

Benralizumab in eosinophilic granulomatosis with polyangiitis complicated by Staphylococcus aureus sepsis

Antonios G. A. Kolios et al.

Summary: Eosinophilic Granulomatosis with Polyangiitis (EGPA) is a small-vessels vasculitis associated with ANCA, characterized by hypereosinophilia and eosinophilic asthma. In cases of life-threatening organ involvement, particularly cardiac and central nervous system (CNS), immediate immunosuppression is required. Antibiotic therapy combined with Benralizumab can be a potential therapeutic option for active EGPA with eosinophil-mediated pathologies in severely ill patients.

CLINICAL IMMUNOLOGY (2021)

Add to Collection

Editorial Material Allergy

Efficacy of Benralizumab and Clinical Course of IgG4 in Eosinophilic Granulomatosis With Polyangiitis

Y. Miyata et al.

JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY (2021)

Add to Collection

Article Respiratory System

Rapid effect of benralizumab in exacerbation of severe eosinophilic asthma associated with eosinophilic granulomatosis with polyangiitis

Carlos Martinez-Rivera et al.

Summary: This case report demonstrates rapid improvement in symptoms and lung function in a patient with severe eosinophilic asthma associated with EGPA using benralizumab. The findings suggest the potential advantage of benralizumab in the treatment of patients with EGPA and severe eosinophilic asthma refractory to conventional treatment.

BMC PULMONARY MEDICINE (2021)

Add to Collection

Review Medicine, General & Internal

Eosinophilic Granulomatosis With Polyangiitis: Dissecting the Pathophysiology

Filippo Fagni et al.

Summary: EGPA is a rare multisystemic disease characterized by vessel inflammation and eosinophilic proliferation. It is divided into different phenotypes based on ANCA status, with diagnosis and treatment implications.

FRONTIERS IN MEDICINE (2021)

Add to Collection

Article Respiratory System

Successful treatment with benralizumab in a patient with eosinophilic granulomatosis with polyangiitis refractory to mepolizumab

Francesco Menzella et al.

Summary: EGPA is a rare multi-organ inflammatory condition characterized by necrotizing eosinophilic granulomatous inflammation. Effective treatment options include oral glucocorticoids, but frequent relapses and side effects are common. There is currently no consensus on dosing and treatment schedules for managing EGPA.

MULTIDISCIPLINARY RESPIRATORY MEDICINE (2021)

Add to Collection

Article Respiratory System